BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 29436681)

  • 1. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
    Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-199a-3p enhances breast cancer cell sensitivity to cisplatin by downregulating TFAM (TFAM).
    Fan X; Zhou S; Zheng M; Deng X; Yi Y; Huang T
    Biomed Pharmacother; 2017 Apr; 88():507-514. PubMed ID: 28126676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.
    Deng Y; Zhao F; Hui L; Li X; Zhang D; Lin W; Chen Z; Ning Y
    J Ovarian Res; 2017 Jul; 10(1):50. PubMed ID: 28743276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1.
    Li Q; Xia X; Ji J; Ma J; Tao L; Mo L; Chen W
    Oncotarget; 2017 May; 8(20):33621-33630. PubMed ID: 28422725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-490-3p sensitizes ovarian cancer cells to cisplatin by directly targeting ABCC2.
    Tian J; Xu YY; Li L; Hao Q
    Am J Transl Res; 2017; 9(3):1127-1138. PubMed ID: 28386339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
    Niu L; Ni H; Hou Y; Du Q; Li H
    Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systems biology approach to identify microRNAs contributing to cisplatin resistance in human ovarian cancer cells.
    Liu W; Wang S; Zhou S; Yang F; Jiang W; Zhang Q; Wang L
    Mol Biosyst; 2017 Oct; 13(11):2268-2276. PubMed ID: 28861582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-489 modulates cisplatin resistance in human ovarian cancer cells by targeting Akt3.
    Wu H; Xiao Z; Zhang H; Wang K; Liu W; Hao Q
    Anticancer Drugs; 2014 Aug; 25(7):799-809. PubMed ID: 24686007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
    Cheng W; Liu T; Wan X; Gao Y; Wang H
    FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
    Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
    Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
    Hu Z; Cai M; Zhang Y; Tao L; Guo R
    Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory mechanism of lncRNA NORAD on proliferation and invasion of ovarian cancer cells through miR-199a-3p.
    Xu C; Zhu LX; Sun DM; Yao H; Han DX
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(4):1672-1681. PubMed ID: 32141533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [miR-129-1-3p reverses cisplatin resistance of HNE1/CDDP human nasopharyngeal carcinoma cells by targeting inhibition of WEE1 kinase].
    Zhang H; Lu J; Jiang C; Lu W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Nov; 35(11):1014-1019. PubMed ID: 31878998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gambogic Acid Inhibits Melanoma through Regulation of miR-199a-3p/ZEB1 Signalling.
    Liang L; Zhang Z; Qin X; Gao Y; Zhao P; Liu J; Zeng W
    Basic Clin Pharmacol Toxicol; 2018 Dec; 123(6):692-703. PubMed ID: 29959879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
    Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
    J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
    Wang X; Li H; Shi J
    Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR).
    Wu D; Huang HJ; He CN; Wang KY
    Int J Gynecol Cancer; 2013 Sep; 23(7):1191-7. PubMed ID: 23851675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting miR-21-3p inhibits proliferation and invasion of ovarian cancer cells.
    Báez-Vega PM; Echevarría Vargas IM; Valiyeva F; Encarnación-Rosado J; Roman A; Flores J; Marcos-Martínez MJ; Vivas-Mejía PE
    Oncotarget; 2016 Jun; 7(24):36321-36337. PubMed ID: 27166999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.